title: Myasthenia gravis and return to flying status.
abstract: BACKGROUND
  Myasthenia gravis (MG) is a common primary disorder of neuromuscular transmission. Although MG was once a fatal disease, today treatment with immunomodulating agents and cholinomimetic medications with good supportive care have improved the prognosis and the ability of patients to adapt to their workplaces, including the flight environment.
  
  
  METHODS
  The diagnosis of MG in two aircrew members illustrates the range of severity for MG from isolated ocular symptoms to relentlessly progressive generalized disease, as well as the unpredictability of the disease and difficulty in treatment. Nevertheless, both patients were returned to limited flying status.
  
  
  CONCLUSIONS
  MG presents the potential for subtle progression with resulting effects on flight performance. In addition to the disease itself, flight surgeons must also consider problems related to treatment and its side effects. Progression and exacerbations of MG can develop during the course of the disease, requiring careful adjustments to treatment regimens. Taking all these factors into consideration, including the unpredictability of this disease, pilots with apparently stabilized MG should nevertheless be assigned only to duties during which the patient would be able to maintain and use his flying capabilities without risking the mission, himself, and other crewmembers.
authors.affiliation: Israeli Air Force Aeromedical Center, Tel-Hashomer, Israel. yuvalk1@hotmail.com
authors.forename: Yuval
authors.initials: Y
authors.lastname: Karmon
authors.forename: Shany
authors.initials: S
authors.lastname: Blum
authors.forename: Ronen
authors.initials: R
authors.lastname: Levite
authors.forename: Erez
authors.initials: E
authors.lastname: Barenboim
authors.forename: Natan
authors.initials: N
authors.lastname: Gadoth
mesh_terms: D000328:Adult; D000337:Aerospace Medicine; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D018450:Disease Progression; D005938:Glucocorticoids / Q000627:therapeutic use*; D006304:Health Status; D006801:Humans; D007557:Israel; D008297:Male; D008875:Middle Aged; D008889:Military Personnel; D009157:Myasthenia Gravis / Q000175:diagnosis / Q000188:drug therapy*; D011241:Prednisone / Q000627:therapeutic use*; D011379:Prognosis; D011729:Pyridostigmine Bromide / Q000627:therapeutic use; D011950:Receptors, Cholinergic / Q000276:immunology; D012720:Severity of Illness Index; D017211:Treatment Failure
chemical_list: D002800:Cholinesterase Inhibitors; D005938:Glucocorticoids; D011950:Receptors, Cholinergic; D011729:Pyridostigmine Bromide; D011241:Prednisone